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Abstract 
Introduction: Diabetes mellitus is a chronic disease characterizes by the absence of insulin production by the body 
or the inability of their effectively use. 
Aim: To determine prevalence of diabetes types, the frequency of glycemic control, identify change in eating habits 
and physical activity, characterize the pharmacological therapy concerning classic and novel therapeutic approaches 
and verify the therapy adherence in diabetics of northeast Portugal. 
Methods: A cross-sectional study was performed by applying an interview to 202 adult diabetics of Trás-os-Montes 
region (Portugal), based on a questionnaire, with MAT scale (measure of adherence to therapy) validated for the 
Portuguese population. 
Results: The results showed 73,8% and 26,2% diabetics of type 2 and type 1, respectively. Most of the total diabetics 
(38,1%) have controlled the glycemic once a day, 60.4% have modified eating habits and 89.7% increased the 
frequency of physical activity. The drugs more used were metformin (63) and insulin (52) and the use of incretin 
mimetics was low (13.9%, 28), with more expression of the association of metformin and vildagliptin (21). The 
prevalence of diabetics adherents to therapy was 92,6%. 
Conclusions: The majority of diabetics adhered to pharmacological therapy and the use of dipeptidyl peptidase IV 
(DPP-4) inhibitors remains low. 
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  Introduction 
     Diabetes mellitus is a disease with an increasing 
prevalence. World Health Organization (WHO) 
estimated that 8.5% adults aged 18 years and older had 
diabetes in 2014 and in 2012 the disease was the direct 
cause of 1.5 million of deaths and high blood glucose 
was the cause of another 2.2 million deaths [1].  
 
     Diabetes is a chronic disease characterize by inability 
of the pancreas to produce enough insulin, the hormone 
that regulates blood sugar, or when the body cannot 
effectively use the insulin produced by pancreas. The 
most common types of diabetes are Type 1 diabetes, 
Gestational diabetes and Type 2 diabetes [1]. 
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     Type 1 diabetes causes remains unclear and the 
symptoms are characterized polyuria, polydipsia, 
constant hunger, weight loss, vision changes and 
fatigue. In this type of diabetes, the incapacity to 
produces insulin requires its daily administration [2,3]. 
 
     Gestational diabetes is characterized by 
hyperglycaemia with blood glucose values above 
normal but below those diagnostic of diabetes, and 
occurs during pregnancy [1].  
 
     Type 2 diabetes is the most prevalent diabetes type 
and results of the body’s ineffective use of insulin. It is 
clearly associated with unhealthy lifestyles such as diets 
rich in fats and carbohydrates and physical inactivity. 
The symptoms are similar to those of Type 1 diabetes 
but are often less marked, which may leads to the under 
diagnosis [2-6]. 
 
     Uncontrolled hyperglycaemias over years leads to 
serious damage of the body's tissues and systems, 
especially in nerves, heart, blood vessels, eyes and 
kidneys, resulting in heart disease, stroke, kidney 
disease, eye problems, nerve damage and foot 
problems. In fact, diabetes is a major cause of blindness, 
kidney failure, heart attacks, stroke and lower limb 
amputation [1]. 
 
     Type 2 diabetes treatment includes an adequate diet 
and physical activity, in order to control blood glucose 
levels and increase the patient's quality of life [2]. 
Additionally, and if these interventions are not 
sufficient, there is a large number of Antidiabetic drugs. 
The glycaemic control in Type 2 diabetes was achieved, 
in most of cases, with oral therapy combinations. For 
that, the available classes are biguanides, sulfonylureas, 
meglitinide derivatives, glitazones, alpha-glucosidase 
inhibitors. In the last 10 years, new drugs and drug 
classes becoming available for disease control such as 
glucagon-like peptide–1 (GLP-1) agonists, selective 
sodium-glucose transporter-2 (SGLT-2) inhibitors and 
dipeptidyl peptidase IV (DPP-4) inhibitors [3,7]. The 
last class, also called incretin mimetics is a recent 
therapy in Portugal and comprises linagliptin, 
saxagliptin, sitagliptin and vildagliptin. These anti-
diabetic drugs are able to decreases postprandial and 
fasting glycaemia, decreases glycosylated hemoglobin 
levels, decreases glucagon release. Additionally 
decrease triglyceride levels, reduces body weight, also 
do not cause significantly hypoglycaemia and are well 
tolerated [3,8,9]. 
 
     According to WHO adherence to long-term therapy 
for chronic illnesses in developed countries averages 
only around 50% [10]. Therapy adherences are usually 
reduced in patients with chronic diseases which is 
associated with the long-term nature of the diseases 
[11]. Studies performed in patients with chronic 
diseases of northern Portugal indicates therapy 
adherence prevalence between 69% and 96%, however 
have been carried out in elderly people whose 
adherence is higher [12-14]. 
 
     In patients with diabetes, in addition to the nature of 
long term therapies, the complex regimen of drugs in 
many patients may compromise therapy adherence. The 
adherence to drug therapy and to healthy lifestyles is 
essential for therapeutic success and the control of the 
diabetes [15]. 
 
     The aim of the present study is determine the 
prevalence of diabetes types, the frequency of glycemic 
control, identify changes in eating habits and physical 
activity, characterize the pharmacological therapy and 
verify the therapy adherence in diabetics of northeast 
Portugal. Other aims include the evaluation of the self-
perception of the diabetic's quality of life and the 
opinion about the Incretin mimetic therapy. 
 
Materials and Methods 
     A cross-sectional and descriptive-correlation study 
was carried out. The sample consisted of 202 diabetics 
of Trás-os-Montes region, in northeastern Portugal, 
over 18 years of age, who were interviewed based on a 
questionnaire, applied from January to April, 2016. 
 
     The questionnaire includes questions to allow 
evaluated the following: a) Socio-demographic 
characteristics such as age, gender, weight, height and 
type of diabetes; b) Eating and physical activity 
behaviors before and after the diagnosis of the disease; 
c) Classic pharmacological therapy and incretin 
mimetics therapy; d) Therapy adherence to anti-
diabetic drugs using the MAT scale (measure of 
adherence to therapy), validated for the Portuguese 
population [16]. To assess therapy adherence, those 
whose average adherence levels were ≥5, were called 
adherent.  
 
     Statistical analysis was performed by using Statistical 
Package for the Social Sciences (SPSS) version 20.0. It 
was used descriptive statistics (absolute and relative 
frequencies) and measures of central tendency and 
dispersion (mean and standard deviation). The level of 
association between variables was studied through the 
qui-square and Fisher tests with a significance level of 
5%. 
 
     The ethical aspects were guaranteed in this study. All 
participants received information explaining the 
research and the ethical considerations and those who 
were willing to participate in the study had signed 
informed consent forms. They were informed that a 
refusal or a termination of their participation would not 
have any negative consequence, being able to withdraw 
from the study at any time. To ensure confidentiality, 
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participant’s codes were used instead of their names, as 
well as the guarantee of collective disclosure of results. 
 
Results 
     The sample is made up of 62.4% women and 37.6% 
men. The majority (73.8%) has type 2 diabetes and the 
rest (26.2%) have type 1 diabetes. Most of the study 
sample registered aged between 71 and 80 years 
(40.6%). 
Glycemic control occurs essentially once daily in 38.1%, 
once a week in 23.8% and monthly in 18.8% of 
diabetics. 
 
Lifestyle and Quality Of Life Self-Perception 
     Figure 1 shows the lifestyle changes of the 
respondents regarding dietary habits and physical 
activity after diagnosis of diabetes. Although 89.6% of 
the participants in this study considered it important to 
change their lifestyles after the diagnosis of diabetes, 
only 60.4% (122) of diabetics changed eating habits, of 
which 92.62% reduced their consumption of sugar and 
53.28% reduced their consumption of carbohydrates 
(Figure 1). On the other hand, of the 68 (33.7%) 
respondents who changed the frequency of physical 
activity practice, 89.7% increased their frequency 
(Figure 2).  
 
 
 Figure 1: Eating and Physical Activity Habits. 
 
 
Figure 2: Changes in Physical Activity Habits. 
    The main reported reasons for the habit modifications 
are for decrease glycaemia levels with 66.9% following 
by 54.7% that refers that the reason is follow a healthy 
lifestyle as can shown in Figure 3.  
 
 
Figure 3: Reasons for Changing Eating and Physical 
Activity Habits. 
 
     Regarding self-perception of the current quality of 
life, the majority (43.6%) affirmed that it is neither good 
nor bad, but 37.1% consider it good. On the other hand, 
52.0% of the respondents stated that they would have a 




     Concerning the use of classical medication, 67.8% of 
the respondents stated that they were taking anti-
diabetics, 4.5% stated that they did not take it, and the 
remaining 27.7% did not know whether to take it or 
not. It is found that metformin is the medicine most 
used in the control of the disease by the respondents 
(n=63, 46.0%), followed by the insulin used by 38.0% 
(n=52) (Figure 4). 
 
 
Figure 4: Classical pharmacological treatments. 
 
     On the other hand, 13.9% (n= 28) of the respondents 
reported taking incretin mimetics of dipeptidyl 
peptidase IV (DPP-4) inhibitors group and the most 
(75.0%) use the combination of metformin and 
vildagliptin (Figure 5). 
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Figure 5: Use of incretin mimetics (pipeptidyl peptidase 
IV (DPP-4) inhibitors). 
     Among diabetics taking dipeptidyl peptidase IV (DPP-
4) inhibitors, 50.0% reported a greater decrease in 
glycaemic levels with this medication. Additionally, 
46.4% and 14.3% said they were satisfied or very 
satisfied, respectively, with this new therapy. 
 
Therapy Adherence and Related Factors 
     Regarding therapy adherence, the mean score of 
responses obtained was 5.67 points (SD = 0.486, 
minimum = 3.29 and maximum = 6.00), which 
translates into a strong adherence to therapy. 
Subsequently, the global values that presented a mean 
of at least 5 points correspond to the adherent and the 
global values with a mean of less than 5 correspond to 
non-adherents. It was obtained that 7.4% were 
considered non-adherent and the majority (92.6%) 
were classified as adherents to the therapeutic regimen. 
Although most of the diabetics in the study sample 
adhere to therapy, 4.0% admitted to being frequently 
careless about the hours of taking medication and 2.5% 
frequently forget to take them (Table 1). 
 
MAT scale items 
   n (%)   
Mean 
Ever Often Frequently Sometimes Rarely Never 
Have you ever forgotten to take the 
medicines for diabetes? 
0(0,0) 0(0,0) 5(2,5) 32(15,8) 50(24,8) 115(56,9) 5,36 
Have you ever been careless with the 
 time of taking the medicines for diabetes? 
0(0,0) 2(1,0) 8(4,0) 34(16,8) 57(28,2) 101(50,0) 5,22 
Have you ever stopped taking the 
 medicines for diabetes for feeling better? 
0(0,0) 2(1,0) 3(1,5) 6(3,0) 13(6,4) 178(88,1) 5,79 
Have you ever stopped taking the  
medicines for diabetes because you felt 
worse? 
0(0,0) 0(0,0) 4(2,0) 3(1,5) 13(6,4) 182(90,1) 5,85 
Have you ever taken more than one 
medicines for diabetes because you felt 
worse? 
0(0,0) 0(0,0) 0(0,0) 7(3,5) 6(3,0) 189(93,6) 5,90 
Did you ever stop the therapy because you 
 let the medicines for diabetes run out? 
0(0,0) 0(0,0) 3(1,5) 8(4,0) 18(8,9) 173(85,6) 5,79 
Have you ever stopped taking the 
 medicines for diabetes for any reason than 
not medical indication? 
0(0,0) 0(0,0) 3(1,5) 8(4,0) 18(8,9) 173(85,6) 5,79 
Table 1: Score of MAT scale items. 
 
     Table 2 shows the related factors to adherence to 
diabetes pharmacological therapy. It was found that the 
male subjects are the most adherent to treatment 
(97.4% male vs. 89.7% female, p= 0.044) and diabetics 
who control glycaemia at least daily, are more adherent 
to therapeutic regimen than those who control it weekly 
(97.5% daily vs 85.5% weekly, p = 0.006). 
 
     It is also verified that age, type of diabetes, altered 
eating habits, importance attributed to altered eating 
habits and practice of physical activity and the self-
perception of current quality of life are not associated 
with therapy adherence (Table 2). 
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Nonadherent Adherent Total 
p-value 
n(%) n(%) n(%) 
Gender 
Female 13(10.3) 113(89.7) 126(100) 
0.044 
Male 2(2.6) 74(97.4) 76(100) 
Age 
≤ 60 years 2(8.0) 23(92.0) 25(100) 
0.999 
61-70 years 3(6.8) 41(93.2) 44(100) 
71-80 years 6(7.3) 76(92.7) 82(100) 
>80 years 4(7.8) 47(92.2) 51(100) 
Diabetes Type 
Type 1 3(5.7) 50(94.3) 53(100) 
0.763 
Type 2 12(8.1) 137(91.9) 149(100) 
Time since diagnosis 
Up to 10 years 7(7.7) 84(92.3) 91(100) 
0.870 From 11 to 20 years 6(8.1) 68(91.9) 74(100) 
More than 20 years 2(5.4) 35(94.6) 37(100) 
Glycemic control 
At least daily 2(2.5) 77(97.5) 79(100) 
0.006 At least once a week 12(14.5) 71(85.5) 83(100) 
Monthly or Annually 1(2.5) 39(97.5) 40(100) 
Changes in eating habits 
No 7(8.8) 73(91.3) 80(100) 
0.561 
Yes 8(6.6) 114(93.4) 122(100) 
Importance in changing 
habits 
No 4(19.0) 17(81.0) 21(100) 
0.055 
Yes 11(6.1) 170(93.9) 181(100) 
Current quality of life 
At least “Good” 3(3.8) 76(96.2) 79(100) 
0.261 “Neither good nor bad” 8(9.1) 80(90.9) 88(100) 
“Bad” or “Very bad” 4(11.4) 31(88.6) 35(100) 
Table 2: Adherence to Diabetes Pharmacological Therapy and related factors. 
 
Discussion and Conclusion 
     The majority of participants in this study are type 2 
diabetics, the type of diabetes that affects more people 
worldwide [1]. Most of diabetics take metformin as 
classic therapy, while a minority use pipeptidyl 
peptidase IV (DPP-4) inhibitors, generally called 
incretin mimetics, and most of them are satisfied with 
this new therapy. These results are in line with the 
recommendations that considered insulin, metformin 
and sulphonylureas as three essential medicines for 
diabetes management [1]. The pipeptidyl peptidase IV 
(DPP-4) inhibitors are less used by several reasons 
which is in according to the literature who consider 
them as second-line antidiabetic therapy [17,18].  
 
     In the present study, the great majority of 
respondents were classified as adherents to the 
pharmacological regimen which are more encouraging 
results than other that, despite distinct methods used, 
indicating that the recommended glycaemic goals are 
been achieved by less than 50% of patients, which may 
be associated with decreased adherence to therapies in 
type 2 diabetics [15]. In another study, 70% patients 
have reported non-adherence to medication schedule 
[19]. Therapy adherence is, in this study, associated 
with the male gender and the daily frequency of 
glycaemic control. Although no statistical association 
with therapy adherence, the changes in eating and 
physical activity has been recognized as important by 
the diabetics. In fact, healthy diet and regular physical 
activity are non-pharmacological therapy requires for 
treated, avoided consequences or delayed diabetes 
disease [1]. 
 
     Overall, the majority of diabetics adheres to 
pharmacological therapy and use mostly metformin and 
insulin. The use of dipeptidyl peptidase IV (DPP-4) 
inhibitors for controlling disease remains low. 
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